Loading
A phase 1/2 trial of Pucotenlimab in melanoma, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.
OH2 Injection in Combination With HX008 for Melanoma. is a phase 1/2 interventional study registered as NCT04616443 by Binhui Biopharmaceutical Co., Ltd., with 60 participants planned, started 2020-12-01 and due to reach its primary completion in 2025-11-30. Interventions recorded: OH2 injection, HX008 injection. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Binhui Biopharmaceutical, Melanoma.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/